About 100 reports

  • OF CONTENTS

In December 2017, the FDA approved Bristol-Myers Squibb' s PD-## inhibitor Opdivo (nivolumab) as an adjuvant treatment for patients with completely resected melanoma with lymph node involvement or metastatic disease.

  • Hepatitis
  • United States
  • Merck & Co., Inc.
  • Novartis AG
  • Roche Group

The offers a wide range of devices and kits for autoimmune diseases worldwide.

  • Endoscope
  • Endoscopic Device
  • World
  • Forecast
  • Smith & Nephew Plc

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • East Asia
  • Japan
  • Forecast
  • Olympus Corporation

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • Brazil
  • South America
  • Forecast
  • Medtronic, Inc.

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • Latin America
  • Mexico
  • North America
  • Forecast

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • Australasia
  • Australia
  • Oceania
  • Forecast

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • China
  • East Asia
  • Forecast
  • Olympus Corporation

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • India
  • South Asia
  • Forecast
  • Olympus Corporation

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • Italy
  • Southern Europe
  • Forecast
  • Olympus Corporation

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • Eastern Europe
  • Russia
  • Forecast
  • Medtronic, Inc.

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • East Asia
  • South Korea
  • Forecast
  • Olympus Corporation

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • Southern Europe
  • Spain
  • Forecast
  • Olympus Corporation

This gives hope for people with MS, as well as other autoimmune diseases.

  • Cancer
  • Hepatitis
  • Sweden
  • Karolinska Institutet Holding
  • Takeda Pharmaceutical Company Limited

Journal of Global Infectious Diseases; ##(##): ##- ##.

  • Hepatitis
  • World
  • Market Size
  • Juno Therapeutics Inc.
  • Merck & Co., Inc.

It can be added into normal Immune Globulin for manufacture of a medicament effective against an autoimmune disease, immunodeficiency syndrome, etc..

  • Hepatitis
  • China
  • Chengdu Ronsen Pharmaceutical Co., Ltd.
  • Hualan Biological Engineering Co., Ltd.
  • Ltd. Hualan Biological Engineering Co., Ltd.
  • Commitment to innovation in technology Availability of affordable and high-quality medicines
  • OTHER PROMINENT VENDORS

About hepatitis Hepatitis is an inflammatory condition that occurs due to infection by hepatitis virus. It predominantly affects the liver and also causes damage to other body parts such as digestive system and brain. Apart from viral infections, hepatitis can also be caused by toxic substances, alcohol consumption, and autoimmune diseases....

  • Hepatitis
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Identifying factors impacting market growth
  • EMEA - Market size and forecast 2017-2022

Some of the most common ear disorders affecting a large group of population (children and aged people) include otitis media, external ear infections, cerumen, and autoimmune ear disease.

  • Endoscope
  • Endoscopic Device
  • World
  • Forecast

It can be added into normal Immune Globulin for manufacture of a medicament effective against an autoimmune disease, immunodeficiency syndrome, etc..

  • Hepatitis
  • China
  • Chengdu Ronsen Pharmaceutical Co., Ltd.
  • Hualan Biological Engineering Co., Ltd.
  • Ltd. Hualan Biological Engineering Co., Ltd.

(USA) ##.

  • Antiviral
  • Hepatitis
  • United States
  • World
  • Market Shares
  • GLOBAL ANTIVIRAL DRUGS MARKET SEGMENTATION BY THERAPIES
  • GLOBAL HEPATITIS THERAPEUTICS MARKET

OTHER CAUSES INCLUDE HEAVY CONSUMPTION OF ALCOHOL, TOXINS, MEDICATIONS, AND OTHER INFECTIONS SUCH AS HIV AND AUTOIMMUNE DISEASES.

  • Hepatitis
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • ViiV Healthcare Ltd.

IFN-based therapies such as Pegintron have adverse side effects and are not recommended for use in patients with advanced liver diseases or autoimmune disorders.

  • Hepatitis
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • 3.6 SOVALDI / HARVONI SALES & FORECAST

The Sovaldi/ Harvoni sales was the second biggest drugs sales in the universe just short of the US$ ##. ## Billion in sales recorded in 2014 by AbbVie' s autoimmune disease drug Humira, which is believed to be the world' s topselling pharmaceutical.

  • Hepatitis
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • PERKINELMER

IT IS THE WORLD LEADER IN IN VITRO DIAGNOSTICS AND MEDICINES FOR CANCER AND TRANSPLANTATION; IT IS ALSO ACTIVE IN SEVERAL OTHER MAJOR THERAPEUTIC AREAS INCLUDING AUTOIMMUNE DISEASE, INFLAMMATORY DISEASE, VIROLOGY, METABOLIC DISORDERS AND DISEASES OF THE CENTRAL NE

  • Hepatitis
  • China
  • Abbott Laboratories, Inc.
  • Immucor, Inc.
  • Roche Group
  • Apr 24, 2017: Tiziana Life Sciences Announces Approval of a Phase II Clinical Trial Protocol for Milciclib in Patients with Hepatocellular Carcinoma
  • Jun 12, 2017: Tiziana Life Sciences Strengthens Unique Research Focus by Appointing Dr Kunwar Shailubhai as Chief Executive Officer

Driven by an obesity epidemic, non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease, affecting one-third of the Western world.

  • Hepatitis
  • Pharmaceutical
  • Therapy
  • United Kingdom
  • Tiziana Life Sciences PLC

Other clinical applications for HLA high resolution typing include disease association with autoimmune diseases and prediction of susceptibility to drug hypersensitivity.

  • Autoimmune Disease
  • Diagnostics
  • Hepatitis
  • China
  • TBG Diagnostics Ltd

ORIBASE PHARMA HAS THE CO-PROPERTY AND EXCLUSIVE RIGHT OF EXPLOITATION OF INVENTIONS OF THE ANTIBODIES THAT WILL BE DEVELOPED IN THE FIELD OF DIAGNOSIS AND TREATMENT OF HUMAN CANCERS, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES.

  • Hepatitis
  • Oncology
  • Pharmaceutical
  • Therapy
  • Exelixis, Inc.
  • Jun 12, 2017: Tiziana Life Sciences Strengthens Unique Research Focus by Appointing Dr Kunwar Shailubhai as Chief Executive Officer

Driven by an obesity epidemic, non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease, affecting one-third of the Western world.

  • Hepatitis
  • Therapy
  • United States
  • Company Financials
  • Tiziana Life Sciences PLC
  • PIPELINE BY NOVARTIS AG, H1 2018

Its drug candidate, PRN##, a reversible covalent BTK inhibitor, is in Phase ## development for pemphigus vulgaris, an orphan autoimmune disease and PRN## is in Phase ## for solid tumors.

  • Cancer
  • Hepatitis
  • United States
  • Product Initiative
  • Eisai Co., Ltd.
  • Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1)
  • Johnson & Johnson - Discovery, 2016

Johnson & Johnson - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘Johnson & Johnson - Product Pipeline Review - 2016’, provides an overview of the Johnson & Johnson’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development...

  • Hepatitis
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • United States
  • R&D Progress

Reasons for premature withdrawal included patient refusal to continue or withdrew consent (## patients), disease remission (## patient) and death due to an acute infection (## patient).

  • Hepatitis
  • Therapy
  • United States
  • Product Initiative
  • REPLICor Inc.